Current Report Filing (8-k)
June 15 2018 - 4:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 12, 2018
MYOKARDIA, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37609
|
|
44-5500552
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
333 Allerton Ave.
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)
(650) 741-0900
(Registrants telephone number, including area code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
The following proposals were submitted to the
stockholders at the 2018 Annual Meeting of Stockholders (the Annual Meeting) of MyoKardia, Inc. (the Company) held on June 12, 2018:
(i) The election of two Class III directors, as nominated by the Board of Directors, to hold office until the 2021 Annual Meeting of Stockholders or until
their successors are duly elected and qualified; and
(ii) The ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered
public accounting firm of the Company for its fiscal year ending December 31, 2018.
The proposals are described in detail in the Companys
Proxy Statement filed with the Securities and Exchange Commission on April 17, 2018.
The number of shares of common stock entitled to vote at the
Annual Meeting was 35,935,980. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 33,553,870. All matters submitted to a vote of the Companys stockholders at the Annual Meeting were approved
and all director nominees were elected.
The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each
matter voted upon are set forth below:
|
(a)
|
Election of Class II Directors.
|
|
|
|
|
|
|
|
|
|
Director Nominee
|
|
Votes For
|
|
|
Votes Withheld
|
|
Tassos Gianakakos
|
|
|
25,265,623
|
|
|
|
3,631,524
|
|
Mary B. Cranston
|
|
|
14,489,091
|
|
|
|
14,408,056
|
|
There were 4,656,723 broker non-votes regarding the election of directors.
|
(b)
|
Ratification of Auditors.
|
Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the
Companys independent registered public accounting firm for the fiscal year ending December 31, 2018. The results of the voting included 33,530,196 votes for, 20,760 votes against, and 2,914 votes abstained. There were zero broker
non-votes regarding this proposal.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: June 15, 2018
|
|
|
|
MyoKardia, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Taylor Harris
|
|
|
|
|
|
|
Taylor Harris
|
|
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
|
|
(principal financial and accounting officer)
|
MyoKardia (NASDAQ:MYOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
MyoKardia (NASDAQ:MYOK)
Historical Stock Chart
From Apr 2023 to Apr 2024